Loading clinical trials...
Loading clinical trials...
Teriflunomide (Aubagio) Effects on Cognitive and Vocational Outcomes, as Related to Neurodegeneration in Multiple Sclerosis: A Prospective, Observational, Single-blinded Study.
Conditions
Locations
1
United States
Buffalo General Hospital, D3
Buffalo, New York, United States
Start Date
February 1, 2014
Primary Completion Date
November 30, 2020
Completion Date
November 30, 2020
Last Updated
September 24, 2021
NCT07225504
NCT06276634
NCT06809192
NCT05359653
NCT07376772
NCT07426991
Lead Sponsor
State University of New York at Buffalo
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions